2-(4-chlorophenyl)-N-methylacetamide | 60336-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-chlorophenyl)-N-methylacetamide
• CAS: 60336-41-6
• 化学式: C₉H₁₀ClNO
• mdl: MFCD02309765
• 分子量: 183.637
• InChiKey: LTADIWWYTXOETE-UHFFFAOYSA-N

物化性质

• 熔点：
  114-116 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  361.8±25.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-(4-chlorophenyl)-N-methylacetamide 在 lithium aluminium tetrahydride 作用下， 生成 N-甲基-4-氯苯乙胺
  参考文献：
  名称：

  Hypoglycemic Agents. II.^1—3 Arylbiguanides

  摘要：

  DOI：

  10.1021/ja01523a059
• 作为产物：
  描述：

  对氯苯乙酸 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 27.0h， 生成 2-(4-chlorophenyl)-N-methylacetamide
  参考文献：
  名称：

  Synthesis of aryl anilinomaleimide based derivatives as glycogen synthase kinase-3β inhibitors with potential role as antidepressant agents

  摘要：

  基于新型苯胺马来酰亚胺衍生物被发现能抑制GSK-3β活性体外，并在动物模型中展现抗抑郁效果。

  DOI：

  10.1039/c5nj02896e

文献信息

• Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds
  申请人：Sattigeri Viswajanani Jitendra

  公开号：US20090075909A1

  公开（公告）日：2009-03-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

  本发明涉及单糖衍生物作为抗炎药剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症性和自身免疫性疾病，例如支气管哮喘、类风湿关节炎、I 型糖尿病、多发性硬化症、移植排斥或牛皮癣。本发明还涉及含有这些单糖衍生物的药物组合物，以及治疗支气管哮喘、慢性阻塞性肺病、类风湿关节炎、多发性硬化症、I 型糖尿病、牛皮癣、移植排斥和其他炎症和/或自身免疫性疾病的方法。
• [EN] ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR<br/>[FR] COMPOSÉS ANTIBIOTIQUES, LEURS FORMULATIONS PHARMACEUTIQUES, AINSI QUE PROCÉDÉS ASSOCIÉS ET UTILISATIONS ASSOCIÉES
  申请人：UNIV FRASER SIMON

  公开号：WO2017075694A1

  公开（公告）日：2017-05-11

  The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant pathogens. Disclosed herein are the compounds of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and their use in the treatment of antimicrobial infection. (Formula (1))

  本发明涉及式(I)的化合物，其中G1至G8如本文所定义。这些化合物是PK抑制剂，因此代表了治疗病原体感染的新方法，包括多药耐药病原体。本文披露了式(I)的化合物，包括含有式(I)的药物组合物以及它们在抗微生物感染治疗中的应用。
• Direct synthesis of amides from nonactivated carboxylic acids using urea as nitrogen source and Mg(NO₃)₂or imidazole as catalysts
  作者：A. Rosie Chhatwal、Helen V. Lomax、A. John Blacker、Jonathan M. J. Williams、Patricia Marcé

  DOI：10.1039/d0sc01317j

  日期：——

  A new method for the direct synthesis of primary and secondary amides from carboxylic acids is described using Mg(NO3)2·6H2O or imidazole as a low-cost and readily available catalyst, and urea as a stable, and easy to manipulate nitrogen source. This methodology is particularly useful for the direct synthesis of primary and methyl amides avoiding the use of ammonia and methylamine gas which can be

  描述了一种由羧酸直接合成伯酰胺和仲酰胺的新方法，使用Mg(NO 3 ) 2 ·6H 2 O或咪唑作为低成本且易于获得的催化剂，以及尿素作为稳定且易于操作的催化剂氮源。该方法对于伯酰胺和甲基酰胺的直接合成特别有用，避免使用操作繁琐的氨和甲胺气体。此外，该转化不需要使用通常需要的偶联剂或活化剂。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。